Immutep Ltd Stock Australian S.E.
Stocks
AU000000PRR9
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 58.95M 41.99M 36.61M 34.48M 31.4M 58.88M 4.02B 413M 159M 2.05B 158M 154M 6.61B | P/E 2027 * |
-2.35x | P/E 2028 * | -3.64x |
|---|---|---|---|---|---|
| Enterprise Value | 4.35M 3.1M 2.7M 2.54M 2.32M 4.34M 297M 30.46M 11.74M 151M 11.64M 11.38M 488M | EV / Sales 2027 * |
1.09x | EV / Sales 2028 * | 8.37x |
| Free-Float |
96.98% | Yield 2027 * |
-
| Yield 2028 * | - |
| 1 day | +4.55% |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 53 | 09/07/2014 |
David Fang
DFI | Director of Finance/CFO | - | 01/03/2018 |
Stephan Winckels
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Marc Voigt
BRD | Director/Board Member | 53 | 09/07/2014 |
Russell Howard
CHM | Chairman | 76 | 17/11/2017 |
Pete Meyers
BRD | Director/Board Member | 57 | 12/02/2014 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.55% | +4.17% | - | - | 41.99M | |
| +0.59% | +2.73% | +1.03% | +28.74% | 46.68B | |
| +1.30% | +1.58% | +44.15% | +35.50% | 44.42B | |
| +0.95% | -6.02% | +342.72% | +532.41% | 41.32B | |
| +4.23% | +3.35% | +9.35% | +94.73% | 41.58B | |
| +1.11% | +1.45% | +11.52% | +45.96% | 30.14B | |
| +1.94% | +4.84% | +25.19% | +159.21% | 17.42B | |
| +0.37% | -10.32% | - | - | 15.6B | |
| +2.12% | +8.18% | +24.78% | +41.21% | 15.54B | |
| +0.24% | +25.43% | -11.57% | - | 14.08B | |
| Average | +1.72% | +3.55% | +55.90% | +133.97% | 29.64B | |
| Weighted average by Cap. | +1.53% | +2.11% | +69.93% | +141.94% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4M 2.85M 2.48M 2.34M 2.13M 4M 273M 28.02M 10.8M 139M 10.7M 10.47M 449M | 3M 2.14M 1.86M 1.75M 1.6M 3M 205M 21.02M 8.1M 104M 8.03M 7.85M 337M |
| Net income | -26.1M -18.59M -16.21M -15.27M -13.9M -26.07M -1.78B -183M -70.47M -907M -69.83M -68.29M -2.93B | -30.47M -21.71M -18.93M -17.83M -16.23M -30.44M -2.08B -213M -82.28M -1.06B -81.54M -79.73M -3.42B |
| Net Debt | -54.6M -38.89M -33.91M -31.94M -29.09M -54.53M -3.73B -382M -147M -1.9B -146M -143M -6.12B | -33.83M -24.1M -21.01M -19.79M -18.02M -33.79M -2.31B -237M -91.35M -1.18B -90.53M -88.52M -3.8B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
